FDA sends "courtesy letters" to three zinc lozenge makers for cold claims.
THREE ZINC LOZENGE MAKERS RECEIVE FDA "COURTESY LETTERS" stating that the products' structure/function claims to treat the common cold are drug claims. The FD&C Act "makes clear that a statement included in labeling...may not claim to diagnose, mitigate, treat, cure or prevent a specific disease or class of diseases," FDA points out in its May 22 letter to Rx Vitamins. "The statement that you are making for Zinc Lozenges suggests that this product is intended for at least one of these purposes in that it claims to reduce the duration of symptoms caused by the common cold," the agency declares
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.